Dr Irving Lerner Weissman
Institute for Stem Cell Biology and Regenerative Medicine Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine Professor of Pathology and Developmental Biology
Dr. Weissman’s research on hematopoiesis, hematologic malignancies and solid tumors has led to several discoveries and the development of new therapies. These include: isolation and transplantation of pure hematopoietic stem-cells (HSCs), development of non-toxic Antibody-based conditioning for HSC transplantation, and the discovery on leukemic stem-cells of CD47 as a â€˜donâ€™t eat meâ€™ signal used by leukemias and all human cancers tested to evade innate immunity. He showed that anti-CD47 blockade unleashes phagocytosis of cancer cells by macrophages, and developed cancer immunotherapy, achieving remarkable results in phase-I clinical trials.